NE
Newbury Pharmaceuticals AB (publ)
NEWBRY.ST · STO
2.26 kr +3.20% (+0.07 kr)
1M -18.89%
Market Cap 58.6M kr
P/E Ratio -
Div. Yield -
ROE 48.85%
Piotroski F-Score Weak
2/9Valuation
50 /100
Fair P/B 1.31x
P/S 16.99x
EV/EBITDA N/A
Growth
96 /100
Growing Book val. growth 10.51%
Rev. growth 135.24%
FCF growth N/A
Profitability
0 /100
Weak Net margin 685.33%
Op. margin 679.21%
FCF margin 337.23%
Quality
0 /100
Poor ROE 48.85%
ROA 26.96%
Asset turnover 0.04x
Debt
58 /100
Moderate Current ratio 1.21x
Int. coverage -58.56x
Debt/Equity 0.00x
Stability
18 /100
Unstable Rev. volatility 97.21%
EPS volatility 71.37%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NEWBRY.ST
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Karl Alexius Tiger Karlsson
Employees
7
Headquarters
Lund